Cancer stem cell (CSC) self-renewing and drug resistance cause treatment failure and tumor recurrence. Osteosarcoma is an aggressive bone tumor characterized by biological and molecular heterogeneity, possibly dependent on CSCs. CSC identification in osteosarcoma and their efficient targeting are still open questions. Spontaneous canine osteosarcoma shares clinical and biological features with the human tumors, representing a model for translational studies. We characterized three CSC-enriched canine osteosarcoma cultures. In serumfree conditions, these CSC cultures grow as anchorage-independent spheroids, show mesenchymal-like properties and in vivo tumorigenicity, recapitulating the heterogeneity of the original osteosarcoma. Osteosarcoma CSCs express stem-related factors (Sox2, Oct4, CD133) and chemokine receptors and ligands (CXCR4, CXCL12) involved in tumor proliferation and self-renewal. Standard drugs for osteosarcoma treatment (doxorubicin and cisplatin) affected CSC-enriched and parental primary cultures, showing different efficacy within tumors. Moreover, metformin, a type-2 diabetes drug, significantly inhibits osteosarcoma CSC viability, migration and self-renewal and, in co-treatment with doxorubicin and cisplatin, enhances drug cytotoxicity. Collectively, we demonstrate that canine osteosarcoma primary cultures contain CSCs exhibiting distinctive sensitivity to anticancer agents, as a reliable experimental model to assay drug efficacy. We also provide proof-of-principle of metformin efficacy, alone or in combination, as pharmacological strategy to target osteosarcoma CSCs.
Introduction
Osteosarcoma (OSA) is the most common primary bone malignancy of young people, predominantly occurring in long bones in areas characterized by proliferating cells and active bone growth [1] . OSA is classified into different histopathologic subtypes (e.g. osteoblastic, fibroblastic, chondroblastic) which, however, have not prognostic or therapeutic relevance [2, 3] . Despite the relative low incidence, OSA accounts for high morbidity and mortality. The therapy of these tumors is extremely complex [4] and the outcome influenced by several factors such as tumor and metastasis sites, the presence of undetectable micrometastases at diagnosis (in more than 80% of patients), extent of lesion and feasibility of complete surgical resection [5] . Neo-adjuvant chemotherapy for localized OSA includes methotrexate, doxorubicin, and cisplatin (MAP), followed by surgery and adjuvant therapy (doxorubicin) to eliminate micro-metastases [6, 7] . Patients bearing localized OSA, and treated with MAP regimen, reach more than 50% overall survival at 5 years, which however did not improve in the last decades [8] ; up to 30% of patients with newly diagnosed OSA have already metastatic spread, commonly in the lungs, making the treatment challenging and survival expectancy very poor (5-year survival of about 20%) [9] . No new chemotherapeutic drugs demonstrate effectiveness in resistant or relapsed OSA (pulmonary recurrence occurs in about 30% of patients) for which no standard second-line strategies are available; thus intense investigations are currently needed to identify both innovative agents active in this disease and the cellular/molecular mechanisms that sustain OSA cell resistance and recurrence.
Different drug resistance mechanisms have been observed in OSA: impairment of drug uptake, enhanced DNA repair system activity, evasion of apoptosis, adaptive signaling from tumor microenvironment, and the presence of cancer stem cells (CSCs) [10] . OSA, as other solid tumors, is cellularly heterogeneous, containing hierarchically organized cells, in which CSCs act as tumor-initiating cells, with intrinsic drug resistance, able to persist in the tumor mass by self-renew and to differentiate into non-tumorigenic cell populations composing the bulk of the tumor [11, 12] . In OSA, several cell types have been proposed as stem-like population, including committed osteo-progenitors or undifferentiated mesenchymal stem cells (MSCs) carrying genetic and/or epigenetic alterations [13] [14] [15] , which enable these cells to escape the control of proliferation and to differentiate into mature bone-forming osteoblasts [16] . CSCs are characterized by self-renewal ability, which allows the isolation and enrichment in vitro of this cell subset and is evaluated by the formation of tumor spheres under non-adherent and serum-free culture conditions [17] , and by in vivo, tumorigenicity, which can be assayed by serial transplantation into immunocompromised mice [18] . Beside functional assays, the expression of stem markers, such as CD133, CD117, Sox2 and Oct4, was also proposed as possible specific CSC marker candidates [19] [20] [21] ; however, a definite phenotype of tumor stem-like cells is still lacking in OSA [12] as well as in other cancers. Importantly, cell populations endowed with stem-like properties were isolated from several pet tumors including canine and feline mammary carcinomas, canine prostate and hepatocellular carcinomas, and OSAs among others [22] [23] [24] [25] [26] [27] [28] [29] [30] , representing a high translational value model for human tumors. Indeed, naturally occurring OSA, the most common primary bone tumor in adult dogs, represents an excellent model for the human disease because shares similar biological and clinical behavior (invasiveness and spreading to lungs, poor median survival time, frequent metastatic disease) [31] [32] [33] . In oncology, the dog model of spontaneous OSA, due to its development in a shorter time than in humans, allowed relevant studies on genomics, diagnosis and drug sensitivity [31] . Moreover, genomic (e.g. TP53, RB1 alterations) and molecular features (dysregulated expression of Met and STAT3, and the chemokine receptor CXCR4, proposed as putative prognostic markers or indicators of metastatic disease) of canine OSAs closely resemble the human disease [34] . Furthermore, the same therapeutic strategies are used in both humans and dogs, and the new drugs under study are proposed to represent valuable approaches for both kind of patients [31, 35] . Both human and canine OSAs contain CSCs that grow in anchorage-independent conditions as sarcospheres and possess tumor-initiating properties, expressing common putative CSCrelated markers and stem-like signatures [30, [36] [37] [38] .
Several in vitro studies report the antiproliferative efficacy of repurposed drugs against CSCs [39, 40] . In particular, metformin, an oral biguanide commonly used as first-line treatment for type 2 diabetes, selectively affects CSC viability in several human tumors [41] [42] [43] [44] [45] [46] [47] [48] . In particular, metformin inhibits OSA cell proliferation, invasiveness, and self-renewal [49] , and sensitizes OSA CSCs to cisplatin [50, 51] . However, in these studies CSC-like cells were mainly derived from continuous cell lines grown in the presence of high fetal bovine serum, an experimental condition which causes the loss of original CSC biological features [52] . To overcome this problem, in this study we performed phenotypic and in vitro and in vivo functional characterization of three primary cultures enriched with tumorigenic CSCs, derived from canine OSAs. Using this model, we investigated the cytotoxic activity of anticancer drugs (cisplatin, doxorubicin) commonly used for OSA treatment, comparing the sensitivity of OSA CSCs and the respective nonstem cell counterparts. In addition, we studied the efficacy of metformin on OSA CSC viability and self-renewal, and the effects achievable by combined treatment with standard drugs and metformin.
Materials and methods

Primary cell cultures of canine OSA and cancer stem cell (CSC) enrichment
Three primary canine OSA cell cultures, named OSA1, OSA2 and OSA3, were isolated from post-surgical tumor specimens at the Department of Animal Pathology of the University of Torino [53] . OSA1 cells derived from osteoblastic productive grade III OSA, while OSA2 and OSA3 cells were isolated from chondroblastic grade III OSAs. The osteoblastic origin of the cultured cells was assessed by morphological observation and alkaline phosphatase activity [53] . Cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM, GIBCO®) supplemented with 10% fetal bovine serum (FBS, EuroClone), penicillin/ streptomycin (EuroClone) and maintained at 37°C in a humidified atmosphere with 5% CO 2 .
Enrichment of OSA primary cultures with stem-like cell subpopulation was performed exploiting CSC low attachment to tissue culture plastic when cultured in "stem cell medium" containing IMDM, 1% FBS, N2-supplement (100×, GIBCO®), epidermal growth factor (EGF, 10 ng/ml, Miltenyi Biotec) and basic fibroblast growth factor (bFGF, 10 ng/ml, Miltenyi Biotec) [38, 54] . This in vitro procedure allows the selection of tumor cells displaying defining stem cell properties of self-renewal and differentiation as prospectively identifiable subpopulations of tumor cells. CSCs from OSA1 and OSA2 have been already partially characterized in vitro in a previous study [30] , while the third one (OSA3) has been used to select putative CSCs for the first time.
Sarcosphere formation assay
Single cell suspensions of primary cultures were seeded in 6-well ultra-low attachment plates (Corning) at a density of 6 × 10 4 cells/well in stem cell medium. After 7 days of incubation, primary spheres (sarcospheres) were obtained. The persistence of self-renewal after long-lasting in vitro culturing was shown by dissociating primary spheres to single cells, which were allowed to generate secondary sarcospheres under the same culture conditions. Serial passaging of first generation spheres, was performed every 7 days of incubation, harvesting the spheres by centrifugation, and dissociation of the pellet to single cells using TrypLE Express Enzyme (GIBCO®), and then expanding them again. To test the effect of metformin on sphere formation, after 7 days of culture to allow sphere generation, sarcospheres were treated with 3 mM metformin and counted after 5 days. Only spheres with at least 40-50 µm were considered. To further demonstrate the activity of metformin, sphere-formation capacity was monitored in the absence or presence of the drug (3 mM): every 7 days sarcospheres formed were disaggregated, cells were counted and replated in fresh medium in the same conditions (in the presence of vehicle or metformin). The number of viable cells was evaluated at every passage.
Immunohistochemistry (IHC)
IHC was performed on 4-μm sections of formalin-fixed paraffinembedded tissue derived from 12 OSAs (9 males and 3 females with M. Gatti et al. Experimental Cell Research 363 (2018) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] mean age 7.7 years, range 0.5-14). As previously described [55] , deparaffinized/rehydrated sections were incubated in citrate-antigen retrieval buffer, nonspecific immunoreactivity was blocked with 10% normal goat serum (Sigma-Aldrich) and primary antibodies applied overnight at 4°C. The following antibodies were used: Oct4 (Abcam), CXCR4 (Sigma-Aldrich), CXCL12 (Abcam), CD117 and STAT3 (SantaCruz Biotechnologies). Real Envision Detection System Peroxidase/DAB +, mouse/rabbit (Dako) was used for the detection according to the manufacturer's instructions. Counterstaining with hematoxylin was performed. For each staining, a negative control, was included without the primary antibody or with rabbit/mouse IgG. Images were captured using a Nikon Coolscope microscope. The intensity of immunoreaction and the percentage of positive cells were evaluated, and a score ranging from 0 to 3 was independently assigned (0 = negative, 1 = low positivity, 2 = positivity, 3 = high positivity), by two pathologists (A.R. and C.C.).
Immunofluorescence (IF)
OSA spheres growing on glass coverslips were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and blocked with NGS (all from Sigma-Aldrich) before adding the following primary antibodies: Oct4 and CXCL12 (Abcam), CXCR4 (SigmaAldrich), osterix (Santa Cruz Biotechnologies), type I collagen (SP1. D8) and osteonectin (AON-1) from Developmental Studies Hybridoma Bank, vimentin (Dako), and Sox2 (Millipore), all diluted 1:100, and CD133 (Milteny Biotec) diluted 1:10, at r.t for 1 h. Fluorochrome-conjugated secondary antibodies (goat anti-mouse and anti-rabbit Alexa Fluor-568 or Alexa Fluor-488, Molecular Probes) were applied, and nuclei were counterstained with DAPI (Sigma-Aldrich) [56] . Negative controls omitting primary antibodies were included in all the experiments. Coverslips were mounted with Mowiol (Sigma-Aldrich) and images were obtained with a DM2500 microscope equipped with a DFC350FX digital camera (Leica Microsystems).
In vitro multilineage differentiation analysis
To study the ability of cells from sarcospheres to differentiate into adipogenic, osteogenic and chondrogenic lineages and verify the enrichment of OSA primary cultures with stem-like cell subpopulation, differentiation analyses were performed. First, to assess the ability to differentiate into non-stem tumor cells, sarcospheres were collected, dissociated into single cells, shifted to IMDM+10%FBS (without growth factors) and cultured for at least 10 days [18, 57] .
To differentiate OSA CSCs towards mesenchymal lineages (osteoblast, chondrocyte and adipocyte), sarcospheres were disaggregated into single-cell suspension and induced to phenotype change using the StemPro® differentiation kits (GIBCO®), as reported [58] . Briefly, cells were seeded into StemPro® Adipogenesis Differentiation medium (GIBCO®) for 14 days, replacing medium every 3 days. Oil Red O (Sigma-Aldrich) staining was used to detect intracellular lipid vacuoles. Osteogenic differentiation was assessed after 21 days of incubation in StemPro® Osteogenesis differentiation medium (GIBCO®) by 2% alizarin red S (Sigma-Aldrich) staining to detect the formation of calcium deposits. Chondrogenic differentiation was monitored after 21 days in StemPro® Chondrogenic differentiation medium (GIBCO®) by staining cultures with 1% Alcian Blue (Sigma-Aldrich) for proteoglycan matrix production.
Tumorigenicity
All animal procedures were carried out under project license in compliance with guidelines approved by Ethical Committee for animal use in cancer research at IRCCS-AOU San Martino-IST (Genova, Italy) and Italian Ministry of Health (no. 327, Dl.vo 116/92 and 412, in accordance with EU Directive 2010/63/EU). Four NOD-SCID mice (Charles River) aged 6-8 weeks were used to test their ability to grow in vivo. Xenografts were established by pseudo-orthotopic inoculation of 1.5 × 10 5 OSA1, OSA2 and OSA3 cells re-suspended in 100 μl Matrigel™ (BD Bioscience) and 100 μl medium, derived either from cells selected in by growing in stem cell medium and cultured as sarcospheres or the respective parental primary cells. Mice were monitored for disease symptoms and sacrificed by CO 2 asphyxiation when weight loss or any other sign of suffering was observed. Excised tumors were divided in two parts: one was fixed in 10% buffered formalin and embedded in paraffin for IHC analysis, the second was cut into small fragments and cell suspension was collected for in vitro culture. Tumorderived single cells forming spheres were re-injected into new recipient mice to verify tumor-forming ability upon serial transplantation.
MTT assay
Cells (4000/well) were plated into 96-well plates, allowed to attach for 24 h, and treated with 1-30 mM metformin, 0.03-30 μM doxorubicin and 0.3-30 μM cisplatin, for 48 h. All drugs were dissolved in sterile water and purchased from Sigma-Aldrich. Mitochondrial activity, as index of cell viability, was evaluated by incubation with MTT (Sigma-Aldrich, stock solution 2 mg/ml) for 2 h, formazan crystals were dissolved in DMSO and absorbance spectrophotometrically measured at 570 nm [59] . IC 50 values were calculated using nonlinear regression curve fit analysis selecting the log (drug) vs. response-variable slope (three parameters) using Prism 5.02 (GraphPad San Diego CA, USA). Each treatment was analyzed in quadruplicate, and the experiments were repeated at least three times.
Colony formation assay
Viable single cells were plated in 100 mm dishes at a density of 450 cells/dish in IMDM+10% FBS medium in the presence or absence of metformin, and allowed to grow for 2 weeks monitoring colony formation [60] . Colonies were fixed and visualized by May-Grunewald Giemsa staining (Sigma-Aldrich). Colony formation efficiency (CFE %) was calculated as: (number of colonies per dish/number of cells seeded per dish) × 100.
Migration assay
Experiments were performed in FluoroBlok™ HTS 96 multiwell culture inserts (8 µm pore, Corning) by seeding 1.5 × 10 4 starved cells on the upper chamber after fluorescent staining with Vybrant™ CFDA SE Cell Tracer Kit (1:1000, ThermoFisher) for 15 min at 37°C. Cells seeded on the top of the filter were pre-treated for 24 h with 3 mM metformin. Complete culture medium containing 10% FBS was used as positive control attractant in the lower chamber, while no serum was added in negative controls. When used as chemoattractant, CXCL12 (25 nM) was added in the lower compartment. Migration was evaluated after o/n incubation by counting migrated cells (3 microscopic fields for each condition, performed in triplicate) with a confocal microscope (BioRad MRC 1024 ES).
Three-dimensional (3D) multicellular tumor spheroid invasion assay
Multicellular tumor spheroids, as 3D structures mimicking a tumor micro-tissue, were generated by hanging drops as reported [61] . Briefly, CSCs were seeded at a density of 1000 cells per 20 μl drop of complete medium. Generated spheroids, highly reproducible in size, were harvested after 72 h, and embedded in 30 μl of Matrigel. that mimics the natural composition of semi-solid matrix into which tumor cells invade from the spheroid body. Drugs or the corresponding vehicles were added to the culture medium containing embedded spheroids placed in 48-well plates and incubated for up to 6 days at 37°C in 5% CO 2 . The extent of cell invasion was monitored daily and quantified by Image J software (https://imagej.nih.gov/ij), measuring the changes in the area of the invasive structures for each spheroid [61] . At least 12 randomly selected spheroids per experimental group were measured in replicate experiments. On day 6, spheroids were stained with propidium iodide (PI) and Vybrant™ CFDA SE Cell Tracer Kit to detect dead and viable cells by confocal microscopy (BioRad MRC 1024 ES).
Statistical analysis
All experiments were repeated at least three times. Data from quantitative experiments are expressed as mean ± s.e.m. Statistical significance between groups was assessed by t-test (unpaired, twotailed) or one-way ANOVA using Prism 5.02. Statistical significance was established at p values < 0.05. For the evaluation of drug interaction, data form MTT assay (as described above) using doxorubicin or cisplatin alone or in combination with metformin, were analyzed using the median-effect method [62] and expressed as the combination index (CI) calculated using CompuSyn software (ComboSyn Inc., Paramus, NJ, USA) where CI < 1, = 1, and > 1 indicates synergism, additive effect and antagonism, respectively. Based on CI, synergy is further refined as moderate synergism (combination index = 0.7-0.9), synergism (combination index = 0.3-0.7), strong synergism (combination index = 0.1-0.3), and very strong synergism (combination index < 0.1) [63, 64] .
Results
Isolation and in vitro expansion of cancer stem-like cells from canine osteosarcoma
Three primary cell cultures were derived from one osteoblastic productive OSA grade III (OSA1), and two chondroblastic OSAs grade III (OSA2 and OSA3) [53] . Grown in FBS-containing medium, all cultures proliferate as adherent monolayers (Fig. 1A) ; however, when cultured as single cell suspension in low serum concentration (1% FBS), supplemented with EGF and bFGF, two growth factors required for the in vitro expansion of normal and cancer stem cells [54] , OSA cells formed, within 7-10 days, non-adherent, multi-cellular spheroids (sarcospheres) (Fig. 1B) . Tumor spheroids showed different morphology: OSA1 formed spherical, compact aggregates, while OSA2 and OSA3 generated less dense and uniform shape and circular spheres (Fig. 1C) . In growth factor-supplemented medium, sarcosphere cells were able to proliferate and survive for long term. Moreover, in these culture conditions OSA cells generate secondary sarcospheres after dissociation, and re-formation passages could be repeated several times (data not shown). This selection allowed the in vitro expansion of an OSA cell subpopulation with morphological and biological characteristics different from the original cell cultures and, being in vitro spherogenic activity considered an indirect index of self-renewal ability, we named these cell subpopulations as OSA1 CSC, OSA2 CSC, and OSA3 CSC (see below for the complete characterization).
Osteosarcoma CSC spheres express osteogenic markers and stemness markers
To test whether OSA CSCs within sarcospheres retain osteogenic potential, we characterized their phenotype by IF for bone-specific markers (Fig. 1D) . Osterix, one of the early osteogenic transcription factors and vimentin, a constituent of the intermediate filament protein family and, typically, a mesenchymal cell marker, were expressed by almost all cells within spheres of the three OSA CSCs. Osteogenic differentiation was explored by detection of late osteogenic lineage proteins such as collagen type I and osteonectin that showed a nonhomogeneous staining pattern: in particular, OSA 1 and OSA 2 CSC spheres contained few scattered type I collagen positive-cells but were negative for osteonectin, contrarily OSA3 CSCs were almost negative for type I collagen and osteonectin-positive (Fig. 1D) . These results indicate that OSA1, OSA2 and OSA 3 spheres contained stem-like cells committed to osteogenic differentiation (maturation), although a complete differentiation was still not detectable (as demonstrated by the low levels of bone extracellular matrix gene osteonectin, and type I collagen).
Being CSC pluripotency associated with the ability to maintain the expression of specific proteins and transcription factors, to further characterize the putative stem-like phenotype of sarcosphere cells, we analyzed by IF the expression of Sox2 and Oct4, two intracellular transcription factors overexpressed by stem cells, and CD133, a stemcell surface marker, (Fig. 2) . OSA1, OSA2 and OSA3 CSC express, although not homogeneously, all the above mentioned markers, thus indicating the prevalence of cells with stem-like phenotype within spheroids (Fig. 2) . In addition, we tested the immunoreactivity for the chemokine receptor CXCR4 and its ligand CXCL12, both overexpressed in several human [65] [66] [67] and canine tumors [55] , contributing to osteosarcoma CSC maintenance, migration, and homing in metastatic sites [68] . IF analysis revealed that both proteins are expressed in the majority of sarcosphere cells (although CXCL12 was detected in less OSA2 cells) (Fig. 2) , confirming the relevance of the CXCL12/CXCR4 axis in OSA. likely in the control and/or modulation of cell stemness. Overall, these analyses corroborated the stem cell phenotype of the spherogenic cells derived from all canine OSA cultures we analyzed.
In vitro differentiation capacity of osteosarcoma sphere cells
Since serum depletion promotes CSC-like phenotype, we tested whether this process was reversible by shifting sarcosphere-derived single cells from OSA1, OSA2 and OSA3 CSCs to the original culture condition, in serum-containing medium. After 10-15 days, CSCs lost anchorage-independent proliferation, grew as monolayers (Fig. 3) , and re-acquired the morphology and shape resembling parental primary OSA cultures (see Fig. 1 ), likely suggesting that OSA sarcospheres harbor stem-like cells able to (re-)differentiate in vitro.
Next, based on the recent evidence suggesting that the OSA cell-oforigin most likely derives from mesenchymal stem cells, the precursor of osteoblasts, rather than osteoblast-committed cells [13] , to explore the differentiation potential of sarcosphere cells, we induced our cultures to differentiate along mesenchymal lineages. Therefore, the putative mesenchymal origin of OSA CSCs should grant this cell subset the ability to differentiate into osteocytes, chondrocytes, and adypocytes.
We evaluated the potential of OSA1, OSA2 and OSA3 CSCs to undergo tri-lineage differentiation by culturing these cells in defined standardized differentiation media (Fig. 3) . Foci of mineralization were visualized by Alizarin Red staining after 21 days of culturing in osteogenic-differentiation conditions in all three OSA CSCs, although at different level: OSA1 CSC formed a stronger deposited mineralized matrix, detectable by more consistent staining than OSA2 and OSA3 cultures (Fig. 3) . Chondrogenic differentiation was demonstrated by Alcian Blue staining after 21 days of culturing in chondrogenic medium: OSA1 and OSA2 CSCs showed solid proteoglycan deposits as index of chondroblastic matrix, while OSA3 CSCs scarcely grew in this culture conditions and differentiation was less evident (Fig. 3) . After 14 days of adipogenic differentiation, OSA1 CSCs were stained with Oil Red O showing several intracellular vacuoles containing lipid drops in most of the cells, whereas in OSA2 and OSA3 CSCs only few cells survived the treatment; however residual adherent cells exhibited intracellular lipid droplets (Fig. 3 ). These data demonstrate that OSA CSCs from all the three tumors studied retain differentiation capacity as expected for both normal and tumor stem cells. Moreover, we can speculate that, in line with predictable individual differences among primary tumors, OSA1 has a more marked mesenchymal phenotype, while OSA2 and OSA3 cells are likely progenitors somewhat more committed to osteogenic rather than chondrogenic or adipogenic differentiation.
Osteosarcoma sphere cells initiate tumors in vivo and xenografts recapitulate the original canine tumor histology
Tumor propagation in vivo is a distinctive hallmark of CSCs (tumorinitiating cells). Thus the gold standard method to characterize CSC subpopulations is the tumorigenic assay after serial transplantation in animal models. To examine the tumorigenic potential, we tested the ability to initiate and support tumor growth in mice of the three OSA CSC-enriched and corresponding primary cultures. Cells (15 × 10 4 ) from OSA1 CSC, OSA2 CSC and OSA3 CSC were injected subcutaneously into NOD-SCID mice. To minimize inter-individual variation and the number of animals to be used, CSCs and non-CSCs obtained from the same OSA were injected into the left and right flank of the same animal, respectively. Tumor development was daily monitored, and animals sacrificed when signs of suffering were observed. OSA2 and OSA3 non-CSC did not develop tumor during the observation period, while OSA1 formed a very small tumor mass (Fig. 4A) . In contrast, the CSC counterpart developed tumors, which become visible after about 1 month from the grafting. Due to OSA CSC tumor development, mice were sacrificed within approximately 50-60 days (OSA1, 53 days; OSA2, 63 days; OSA3, 56 days). The weight of xenograft tumors collected at the end of the experiments is reported in Fig. 4A . These results confirm that sarcospheres are enriched with CSCs exhibiting enhanced tumorigenic potential and that parental cell cultures might contain a too small stem cell fraction to generate tumors.
One of the key features of CSCs is the ability to reproduce in xenotransplants the tumor from which they were isolated. We therefore compared the histology of tumors developed in mice with that of canine original OSA. As shown in Fig. 4B , H&E analysis revealed that OSA1, OSA2 and OSA3 CSC-derived tumors closely reproduced the histotype of the original OSA: tumor osteogenic (OSA1) and chondroblastic areas (OSA2 and OSA3) were observed and confirmed the resemblance with original lesion in dogs, including the presence of extensive areas of osteoid matrix formed by tumoral osteoblasts or atypical cartilage in the OSA of chondroblastic pattern.
To further characterize the phenotype of xenografts, we assessed, by semi-quantitative IHC score (see Materials & Methods), the immunoreactivity for relevant markers associated with OSA tumorigenesis and/or stemness, including the mesenchymal stem cell marker CD117, the transcription factor Oct4 and STAT3 frequently overexpressed in human and canine OSA cell lines [69, 70] , and the tumor metastasisassociated chemokine/receptor pair CXCL12/CXCR4 [71] (Table in Fig. 5A ). All these markers are expressed in mice tumors formed by OSA1, OSA2 and OSA3 CSCs, although at different levels of abundance and distribution throughout the tissues (Fig. 5B) . To verify whether the OSA CSC tumor model we developed reflects the general histological and immunohistochemical features of canine OSAs, we evaluated the expression of the same markers in a series of canine OSAs. To this aim, sections of 12 canine OSAs, including the three initial tumors from which we isolated the cell cultures, were studied. Animal and tumor characteristics are reported in Supplementary Table 1 . The analysis of the expression pattern of CXCR4 (11/12 score 1 and 1/12 score 2), CXCL12 (7 score 1 and 5 score 2), Oct4 (9 score 1 and 3 score 2) and STAT3 (9 score 1 and 2 score 2) showed a marked immunopositivity, although detectable at different levels, whereas CD117 (1 score 2, 4 score 1 and 7 score 0) was detected in a lower number of samples (5/ 12). Overall, these data confirm that tumors obtained by CSC xenografts maintain the general phenotype of canine OSAs.
Osteosarcoma CSCs retain tumor-forming potential during serial in vivo transplantation
CSC tumorigenicity should be retained, or even increased, after serial transplantation due to in vivo enrichment in tumor-initiating cell subpopulations. Since a small tumor was obtained only after xenograft of OSA1 cells non-enriched in CSCs, we analyzed the tumorigenicity of OSA1 CSC and OSA1 cells isolated from first xenografts into new recipient mice. OSA1 cells isolated from mice tumors were re-cultured in stem cell permissive medium (containing EGF and bFGF), confirming that cells from tumors originated from OSA CSCs proliferate in vitro as spheroids (data not shown). Xenografted OSA1 not enriched in CSC were collected and cultured again in medium with serum. Both cell cultures re-implanted in mice developed tumors (Fig. 6A) , which at the sacrifice of animals (after 56 days) were much larger than those developed after the first in vivo passage (see Fig. 5A ), suggesting an increased tumorigenic potential likely induced by an enrichment of tumor-initiating CSCs. Importantly, also the cells derived from OSA1 non-CSC (original culture) xenografts, which developed very small tumors in the first round of in vivo growth (Fig. 5) , gave origin to large tumors in the second round (Fig. 6A) , further confirming that the in vivo growth contribute to the selection and enrichment in tumor-initiating cells also starting with very low number of cells endowed with tumorigenic potential. Tumors developed after the first and second transplants showed the same histology (data not shown). Comparing immunohistochemistry results on sections from first and second injection, we observed that scores of CD117, STAT3, CXCR4 and CXCL12 increased, while Oct4 levels did not change in OSA1 non CSC-derived tumors and decreased in OSA1 CSC xenografts (Fig. 6C ). Altogether these findings suggest that in vivo growth not only preserves but also enhances CSC content within OSA cell population.
Doxorubicin and cisplatin decrease cell viability of osteosarcoma CSCs
The difference in sensitivity between OSA CSCs and non-CSCs toward clinically relevant drugs (doxorubicin, cisplatin) was tested using the MTT assay. In order to allow a better cellular and biochemical evaluation, experiments were performed on short-term monolayer cultures obtained after disaggregation of sarcospheres and seeding cells on Matrigel to facilitate temporary adhesion prior drug exposure; this procedure was previously reported do not interfere with CSC features [18, 57] .
OSA1, OSA2 and OSA3 CSCs, and their respective parental cultures, were treated with increasing concentrations of doxorubicin (range 0.03-30 µM) and cisplatin (0.3-30 µM) for 48 h (Fig. 7) . Dose-response curves indicate that doxorubicin caused a concentration-dependent reduction of cell viability in all the OSA cultures, showing very slight differences among CSC subsets and original cultures as far IC 50 values (OSA1 CSC 0.8 μM vs. OSA1 1 μM; OSA2 CSC 0.2 μM vs. OSA2 0.1 μM; OSA3 CSC 0.2 μM vs. OSA3 0.1 μM) (Fig. 7A) .
The cytotoxic effect of cisplatin (Fig. 7B ) showed higher IC 50 for OSA2 CSC and OSA3 CSCs (12.5 μM and 12.8 μM, respectively) than the respective original non-CSCs (OSA2 4.3 μM; OSA3 3.1 μM), highlighting the expected increased drug resistance (about 3-4 fold) which characterizes CSCs. On the contrary, OSA1 parental cells and CSCs exhibited similar dose-response curves and IC 50 values (9.2 μM and 9.1 μM, respectively) (Fig. 7B) .
Metformin inhibits survival, migration, and self-renewal of OSA CSCs
Recent evidence indicates that metformin, an oral hypoglycemic drug, may reduce cell growth and survival in different tumors, including OSA, selectively affecting CSCs [30, 49, 51, 72] . Therefore, we compared the different sensitivity of OSA CSCs and non-CSCs to increasing concentrations of metformin (0.3-30 mM, for 48 h) (Fig. 8A) . Metformin reduced cell viability in a dose-dependent manner (about −75% for the highest concentration tested), reaching IC 50 values of 2.4 mM and 1.8 mM for OSA1 CSC and OSA2 CSC, respectively, which was a slightly more potent response as compared to OSA1 (IC 50 =7.2 mM) and OSA2 (IC 50 =2.2 mM) non-CSCs. Conversely, both OSA3 and OSA3 CSCs showed lower sensitivity to metformin (−35% viability at 30 mM), with IC 50 not evaluable.
To further define the biological effects of metformin on OSA cells, we performed trans-well migration assay in OSA1 CSC and non-CSC cultures (Fig. 8B) ; in these experiments we used a metformin concentration (3 mM) close to the IC 50 for OSA1, to limit the direct cytotoxicity induced by higher concentrations of the drug. Metformin treatment drastically decreased the migration of OSA1 CSCs, while a lower effect, although statistically significant, was observed in the corresponding differentiated culture.
The effect of metformin on stemness features was also analyzed, only in responsive OSA CSC cultures, evaluating in vitro the impact of the drug on clonal growth ability, measuring the colony-forming efficiency (CFE), and self-renew potential, assessing the ability to generate spheroids after serial in vitro passages (Fig. 9A-B-C) .
CFE evaluation in OSA1 and OSA2 CSCs was performed after 14 days of exposure to 3 mM metformin, to allow cells to generate visible colonies, metformin treatment induced a marked reduction in colony formation as compared to control cultures in both OSA1 (CFE 19% vs. 43%) and OSA2 (CFE 1% vs. 29%) (Fig. 9A) .
To determine whether metformin affects the ability of OSA CSCs to grow as sarcospheres under serum-free medium culturing conditions (using low adhesion plates), OSA1 and OSA2 CSC spheroids, allowed to grow for 7 days, were treated with metformin (3 mM) for further 5 days observing reduction of the number of spheres in both cultures as compared to untreated cells (Fig. 9B) . In order to study the long-term effects of metformin on self-renewal ability, primary spheres were dissociated into single cells, treated with vehicle or metformin (3 mM for 48 h) and allowed to grow for further 7 days until formation of secondary spheres. This procedure was repeated for up to 6 cycles of dissociation/formation in the presence or absence of metformin, and total cells composing spheres were counted: untreated OSA1 CSC and OSA2 CSC showed a constant ability to self-renew at all the time points maintaining the same efficiency to generate new sarcospheres even after 6 passages (Fig. 9C) . Conversely, metformin treatment completely impaired self-renewal of OSA1 CSCs that after only two passages were no longer able to form new spheroids, and progressively reduced this ability in OSA2 CSCs over passages (Fig. 9C) .
Collectively these results indicate that metformin significantly inhibits both the growth of primary spheroids and sphere generations in OSA1 and OSA2 CSCs, suggesting that the treatment causes the depletion of the stem cell subpopulation within OSA cultures.
Metformin enhances doxorubicin and cisplatin cytotoxicity and suppresses 3D-invasion ability of OSA CSCs
Metformin was reported to increase CSC sensitivity to standard anticancer agents, likely circumventing drug resistance [73, 74] . Thus we evaluated whether metformin acts as OSA CSC sensitizer toward the cytotoxic effects of doxorubicin and cisplatin. Metformin-sensitive OSA CSCs were exposed to each drug alone or to combinations of doxorubicin or cisplatin with metformin. After 48 h cell viability was assayed by MTT test. Cisplatin-and doxorubicin-induced cytotoxicity was comparably potentiated by co-treatment with metformin, in OSA1 and OSA2 CSCs, resulting in approximately 10-40% potentiation of the cytotoxicity of both drugs (Fig. 10A-B) . Quantitative determination of the combination effect was evaluated using the Chou-Talalay's CI method where CI < 1 is index of synergistic activity between the drugs analyzed [62] . We observed that for concentrations corresponding to the IC 50 values CIs were 0.78 and 0.70 for the association of doxorubicin and metformin, and 0.68 for the association of cisplatin and metformin, in OSA1 and OSA2 CSCs, respectively. These results support that the administration of metformin induces a moderate synergism with both cytotoxic drugs. 
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Next we investigated the invasive ability of OSA CSCs, a clinical feature of osteosarcoma, by an in vitro 3D-assay in which the establishment of cell-cell and cell-extracellular matrix interactions allows a more close recapitulation of the in vivo situation. Metformin, cisplatin and their combination were applied to the OSA1 CSC spheroids embedded into 3D Matrigel, and the impact on cell invasion was visualized microscopically (Fig. 10C ) and quantified by ImageJ software (Fig. 10D ). Proliferation and outgrowth from the spheroids of untreated CSC sarcospheres increased over the time (up to 6 days) suggesting their high ability to invade the surrounding matrix. Conversely, single drug or drug combination treated sarcospheres showed a significant time-dependent inhibition of invaded areas (Fig. 10D) . We then investigate cell viability of 3D spheroids, by immunofluorescence staining with PI (to identify dead cells) and the viable cell tracer CFSE DA and confocal microscopy analysis (Fig. 10E) , observing that control CSC movement through the 3D matrix is sustained by live cells, while treatment impaired both cell viability and invasiveness.
Metformin inhibits CXCL12-dependent proliferation and migration of OSA CSCs
Based on the biological relevance of CXCL12/CXCR4 axis in OSA, particularly in metastasis, and the expression of this ligand/receptor pair in OSA CSC cultures, we explored the functional role of CXCL12 in OSA CSCs. The binding of CXCL12 to CXCR4 induces various intracellular signaling related to CSC survival, proliferation, and migration [40] . First, we assayed cell growth in starved OSA CSCs stimulated with CXCL12 and treated with metformin for 48 h: the chemokine increased cell proliferation rate, mainly in OSA1, while in OSA2 this effect was not statistically significant. This effect that was significantly inhibited by metformin in both OSA1 and OSA2 CSC (Fig. 11A) . Similar results, although less evident, were also observed in OSA1 and OSA2 non-CSC cultures Fig. 11A .
Next we determined the impact of metformin on CXCL12-dependent OSA CSC migration using trans-well migration assay. Cells were treated with metformin (3 mM, 24 h) in the presence or absence of CXCL12. Untreated OSA1 CSCs showed significant migratory properties which were highly increased when CXCL12 was added in the lower chamber as chemoattractant stimulus (Fig. 11B, left panel) . Both basal and CXCL12-dependent migration of OSA1 CSCs was decreased by metformin treatment (Fig. 11B, left panel) . Importantly, CXCL12 stimulation as well as metformin exposure did not affect migration of OSA1 non-CSCs which also in basal conditions showed a very limited migratory activity (Fig. 11B, right panel) . These data support the powerful CSC metastatic potential that was much less evident in the differentiated counterpart. These results confirm that CXCL12 is a key signal to promote the survival and migration of OSA stem cells, which can be significantly impaired by metformin.
Discussion
OSA is a mesenchymal malignancy of bones that shares genetic and molecular alterations, histopathology, frequency of microscopic metastases at diagnosis, and clinical behavior in humans and dogs [31] . Conventional chemotherapeutic agents (including cisplatin and doxorubicin) prolong OSA patient's lifespan without increasing survival rate, which remains poor due to development of microscopic or diffuse chemotherapy-resistant metastases [75] . Therefore, alterative adjuvant therapies for improving management of OSA progression are urgently warranted. CSC model proposes that a subset of tumorigenic cells endowed with stem-like properties drives tumor initiation, metastasis, drug resistance, and recurrence. This model gained increasing relevance in many solid cancers, including OSA, likely representing a biological correlate for the aggressive clinical behavior of these tumors. Isolation and characterization of CSCs represents a key step to study OSA pathogenesis and biology and develop more efficacious therapies. In particular, the identification of human and canine CSCs derived from surgical tissues of OSA contributed to clarify their stem-like features and, prospectively, to develop targeted drugs to eradicate this cell subpopulation [30, 76, 77] .
In the current study we assessed the biological and pharmacological properties of three patient-derived canine OSA cultures. All cultures showed ability to grow as spheroids in growth factor-containing medium, forming either compact spheres or loose aggregates, which retained self-renewal ability for multiple passages. Spherogenesis has been indeed exploited as one of the methods to identify CSCs in vitro, reflecting the capacity of cells endowed with stem-like properties to grow under non-adherent conditions. In particular, spherogenesis was used to identify, by self renew ability, CSC subsets in cell lines and primary tumors from human and canine OSA [11, 38, 77] , as well as from several other cancer types [78, 79] . In vitro self-renewal ability is not exclusive for CSCs [80] , thus in vivo tumorigenicity of OSA CSC cultures assessed after various enrichment approaches (expression and activity of aldehyde dehydrogenase, side population isolation, spherogenesis, differential marker expression) [81] [82] [83] [84] , represents the crucial method to validate putative CSCs. In particular, the serial transplantation of low number of CSC candidates into immunocompromised mice (tumor-initiating activity) is, to date, considered the only definitive proof of the presence of CSCs in a given culture. We report that cells isolated from canine primary OSA, and grown in vitro as sarcospheres, possess high tumorigenic capacity in vivo. OSA1, OSA2 and OSA3 cultures xenotransplanted in mice, achieved 100% engraftment and developed tumors which recapitulate the original tumor histology.
Tumor development was obtained using significantly lower cells (15×10 4 ) than reported in other studies (e.g. 3×10 6 cells of human osteosarcoma 3AB-OS CSCs isolated from human osteosarcoma MG63 cells, [85] , or a subset of OSA cells sorted from OS99-1 cell line for ALDH enzymatic activity, in which tumor formation was highly dependent on the number of injected cells, likely suggesting that tumorigenic cells were extremely rare [86] ). The tumor-initiating ability of sarcosphere cells, also considering that the parental primary cultures were not able to consistently give rise to tumors in the same experimental conditions, definitely demonstrates the stem nature of these OSA cultures. Moreover, OSA cells obtained from excised xenografts re-cultured in vitro exhibited stem-cell like functional characteristics such as spherogenesis. Second transplant of OSA1 CSCs successfully engrafts and initiates tumor in new recipient mice, preserving the original histopathologic appearance of original canine OSA, also observed in the primary xenografts, indicating that the in vitro experimental conditions we adopted do not impair tumor-initiating potential of these cells. OSA1 non-CSCs derived from primary xenograft tumors formed secondary neoplasms with a higher efficiency than the first injection (in which only small tumors developed) suggesting that in vivo growth favors the amplification of the CSC-like population, as also shown by the increased detection of stem cell markers in histological preparations from the tumors developed after the second injection.
The observation that, differently from CSCs, the first injection of non-CSCs failed to form consistent tumors suggests that sarcosphere cells are essentially different from their original counterparts, and initial OSA primary cultures contain a limited number of CSCs among the large number of non-CSCs; conversely, CSC subpopulations are enriched in vitro by stem-permissive culturing and in vivo by transplantation in mice, and can be found in both conditions after the second mouse transplant. By enriching the cultures in OSA CSC subpopulation, xenografts enhance the aggressive and self-renewing potential of these Fig. 9 . Metformin inhibits the self-renewal of osteosarcoma CSCs. A) Colony forming efficiency (CFE) in OSA1 and OSA2 CSC was evaluated in the presence of 3 mM metformin or vehicle: CFE (%) was significantly lower in treated cells vs. controls (*p < 0.05; **p < 0.01). Representative photographs of colonies are reported. Data represent mean ± s.e.m. B) Sarcospheres formed by OSA1 and OSA2 CSC were treated with 3 mM metformin or vehicle, and counted after 5 days of treatment: the number of sarcospheres was significantly reduced in treated cells vs. controls (*p < 0.05). Data represent mean ± s.e.m. C) Sphereforming of OSA1 CSC (left panel) and OSA2 CSC (right panel) capacity was evaluated in the absence or presence of metformin (3 mM): every 7 days sarcospheres were dissociated to single cell suspension and cells were counted and re-plated in fresh medium in the same. The number of viable cells composing spheres was counted for up to six passages. Data represent mean ± s.e.m. (*p < 0.05; **p < 0.01; ***P < 0.001).
(caption on next page) M. Gatti et al. Experimental Cell Research 363 (2018) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] cells, and amplify the proportion of cells expressing proteins able to sustain tumor growth and stemness (i.e. Oct4, CD117, STAT3, CXCR4, CXCL12). The differential tumor-initiating ability between CSCs and non-CSCs was previously reported, nevertheless a direct confrontation between the two populations derived from the same primary tumor was rarely performed. Murase et al. detected higher tumorigenic ability of sorted side population cells from the bone malignant fibrous histiocytoma cell line MFH2003 compared to the main population cells [82] . Mesenchymal tumor transplantation (1 osteosarcoma, and 2 malignant fibrous histocytomas, 1 synovial sarcoma) into NOD/SCID mice showed that tumors were generated with higher frequency and smaller numbers of side population cells as compared with main population cells [87] . Although a definitive panel of antigens unequivocally identifying CSCs in OSA and other solid cancers is not available [88] , we combined tumorigenic and spherogenic activities with the analysis of the expression of some stem-related markers, to assess changes in CSC content after in vivo growth. We show the concomitant expression of CD133, Oct4, and Sox2 in OSA spheroids, suggestive of stem-cell like [83, 89, 90] including canine OSA [77, 91] . In particular, CD133 expression has been correlated with the gain of tumorigenic activity by OSA cells [84] , although it has to be remarked that both CD133-positive and -negative cells are able to propagate tumors in vivo [92, 93] . On the whole, these results support that a combination of CD133 + with other pluripotency factors characterize the stem-like phenotype of OSA CSCs. CSCs are also responsible for the formation of metastasis. Among proliferation-and metastasis-associated proteins in CSCs, the cytokine CXCL12 and its receptor CXCR4 contribute to bone sarcoma progression and metastatic diffusion [94] . Few studies explored the biological relevance of the CXCL12/CXCR4 axis in canine OSA [95] , showing high expression of both proteins similarly to other canine solid tumors [55] . In the present study, CXCL12/CXCR4 expression within sarcospheres well-matches with their diffuse detection in tumor xenografts and Fig. 10 . Metformin enhances antiproliferative effects and inhibition of invasion of cytotoxic drugs in a 3D setting. A) OSA1 CSC and B) OSA2 CSC were treated with metformin (Met), doxorubicin (Dox) or cisplatin (CDDP) alone, in combination with metformin (at concentrations corresponding to the IC 50 for each drug) or vehicle, for 48 h. Cell viability was evaluated by MTT assay. Data represent the mean ± s.e.m., as % of controls taken as 100% (*p < 0.05; **p < 0.01). C) Representative time-course 3D invasion by OSA1 spheroid cells showing the increase of spheroid size and invasive behavior, that was inhibited by drug treatments. OSA1 CSC spheroids were embedded in Matrigel and maintained in complete medium containing either vehicle (CTR) or 3 mM metformin (Met) and 10 μM cisplatin (CDDP). Invasion area was calculated at day1-3-4 and 6. D) Quantification of invasion by image analysis using ImageJ software. Bar graphs display the area of invasion of CTR or treated spheroids over the compact spheroid area and are expressed as % of the mean ± s.e.m. (ANOVA p < 0.001, Tukey's post-hoc test vs. CTR **p < 0.01; ***p < 0.001). E) Representative confocal images of 3D spheroids stained for viability after 6 days of treatment. Live/dead stains used were CFSE DA (green) and PI (red). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) original OSA tissues of the corresponding dogs (see Tables), suggesting that the regulation of CSC invasive behavior by this chemokine system involve autocrine/paracrine activity besides the chemokinergic stimuli produced by tumor microenvironment. This hypothesis is supported by our observation that CXCL12 stimulates OSA CSC proliferation and migration, representing a chemotactic factor likely directing the migration of CXCR4-positive CSCs toward CXCL12 producing organs.
The complexity of OSA CSC characterization also resides in the originating cell types: mesenchymal cells are one of the cell populations which drive OSA development [13] , since these cells are involved in normal bone formation by differentiation into osteoblasts and possibly also into adipocytes and chondrocytes. We show that canine OSA sarcosphere cells possess multipotency, with OSA1 CSCs able to differentiate in all the three lineages, and OSA2 and OSA3 CSCs showing higher propensity to differentiate into osteoblasts than in chondrocytes and adypocytes. Overall these findings suggest that OSA CSCs retain a different degree of mesenchymal features, correlated with the stage of differentiation of parental cells or the histologic subtype, highlighting that intrinsic heterogeneity of individual tumors may reflect the diverse properties of CSCs. The mesenchymal phenotype of canine OSA CSCs is also suggested by vimentin expression, the most widely accepted mesenchymal marker that is down-regulated in fully differentiated osteoblasts [96] . Moreover, all OSA sarcosphere cells also express osterix, an early/middle osteogenic regulator, which indicates that canine OSA CSCs are likely derived by osteogenic progenitors [97] . The presence of scattered positive cells for type 1 collagen, a late osteogenic marker, in OSA1 and OSA2 spheroids, further confirms the predominance of nonterminally differentiated OSA cells. We therefore propose that CSC cultures isolated form the three OSAs are composed of tumor-initiating cells at distinct differentiation stage, but showing a common, although not identical, phenotype.
The prediction of treatment response in aggressive tumors is still an unmet need also because cytotoxicity in vitro assays routinely performed on established cancer cell lines or, rarely, on primary cultures deriving from bulk tumor cells, which have a low translational value [52] . In particular, these models neglect the chemo-sensitivity profile of the minority CSC population which may significantly differ from that of other tumor cell populations. Indeed, although chemo-resistance is not a defining feature for CSC isolation, it could be considered as a relevant CSC property [98] . This issue is even more critical in OSA whose lethality is mainly due to the early onset of metastases and drug resistance. In our study, IC 50 calculations of doxorubicin and cisplatin cytotoxicity, the chemotherapy regimen used in both humans and dogs, showed that canine OSA CSCs are generally less sensitive than the corresponding parental cells, although the difference was significantly higher for cisplatin than for doxorubicin. Previous studies reported that CSCs isolated from OSA cell lines are more resistant to doxorubicin [99] . CSC originating cell type may contribute to the drug responsivity (e.g. CSCs isolated from established, long-term culture cell lines tend to be more resistant to drugs, because of the more differentiated phenotype or adaptation to in vitro culture conditions), as also observed in glioblastoma CSCs [100] . On the contrary, our CSC cultures exhibited a marked resistance to cisplatin, as observed in stem-like populations from human sarcoma cell lines [99] , and in agreement with the observation that cisplatin-resistant OSA cells exhibited stem-like characteristics both in vitro and in vivo, which are not observed in cisplatinresponsive cells [101] .
Repositioning of metformin as antitumor drug [40] was related to the ability to preferentially affect CSC proliferation and survival [45] [46] [47] . AMPK activation, and the consequent inhibition of mTOR signaling, was the first proposed mechanism of metformin activity on CSCs [102] , but several AMPK-independent pathways have been also suggested [45, 103] . Here we report that metformin significantly impairs survival, migration, and spherogenesis of canine OSA1 and OSA2 CSCs, also when CXCL12, a relevant mediator of OSA progression a diffusion in vivo, was used as proliferative and invasive stimulus. These data support that, besides an antiproliferative and antimetastatic effects, metformin exerts also a direct inhibition of self-renewal. Similar results were obtained in stem-like cells derived from the MG63 cell line, canine mammary carcinoma, human hepatocellular carcinoma or human glioblastoma [28, 47, 49, 104] . Unexpectedly, OSA3 CSCs were less sensitive to metformin. We do not have an explanation for this difference, but it is noteworthy that these individual pharmacological diversities are evidenced only using cells isolated from primary tumors, which thus should represent the more reliable model to translate preclinical data to clinical trials.
The high level of intra-tumor heterogeneity of OSA and plasticity of CSCs, which dynamically can undergo differentiation and dedifferentiation [105] , highlights how ideal therapeutic compounds or drug combination must suppress the survival and proliferation of both CSCs and non-CSCs, and metformin, targeting both cancer cell subsets, prospectively provides a rationale for novel therapeutic options against cancer progression. The chemo-sensitizing/adjuvant role of metformin has been postulated in various cancers however, beside preliminary encouraging data, its impact on tumor response is still under investigation [106] . For example, metformin co-treatment enhanced antiproliferative and pro-apoptotic effects of trichostatin A and simvastatin on OSA [107, 108] . In our experimental model, the treatment with metformin sensitizes OSA1 and OSA2 CSCs to cisplatin and doxorubicin cytotoxic effects, as also reported in stem-like cells derived from human OSA cell lines [50, 51] .
Moreover, when OSA CSCs are grown as multicellular spheroids into 3D extracellular matrix, to mimic the in vivo tumor invasive growth in a more realistic model to study the effect of cytotoxic drugs [109] , metformin alone or in combination with cisplatin abolished cell invasion into the surrounding matrix, impairing the invasive phenotype of OSA, the prerequisite for its metastatic spreading. These data support the development of novel clinical trials in which the adjuvant activity of metformin on cytotoxic drug activity may represent a novel therapeutic approach for the treatment of OSA.
Conclusions
In summary, we demonstrate that canine naturally-occurring OSAs contain tumorigenic stem-like cells with phenotypes distinct from the non-tumorigenic cells composing the tumor mass. These peculiar stemlike features, determining inter-tumor heterogeneity, are preserved in long-term culture in vitro and are at the basis of the ability to recapitulate the original tumor in vivo. Metformin suppresses viability of OSA CSC and parental cells in vitro, and combination treatment with metformin and conventional drugs improve cytotoxic drug response, suppressing both CSC self-renewal and proliferation. Conceivably, results obtained in canine OSA support their relevance in veterinary oncology and serve as preclinical basis for future human therapy strategies.
